Study leverages deep learning-enabled analysis
of the aggregation of real-world multimodal data to validate
predictive signatures associated with response to immunotherapy and
prognosis of patients with stage IV non-small cell lung
cancer
Nearly 20 participating sites activated
worldwide with over 500 patients recruited to date. Early findings
conceptually validate the potential for multimodal signatures to
predict response to immuno-chemotherapy with promising first
results
New agreement signed with GE Healthcare to
utilize Imaging Fabric to further accelerate radiomics
analysis workflows in the context of the study
BOSTON and LAUSANNE, Switzerland, June 6, 2022
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), the creator of a
global data pooling and knowledge sharing platform that advances
data-driven medicine, provides an update on its multimodal
DEEP-Lung-IV clinical study (NCT04994795) at the 2022 American
Society of Clinical Oncology (ASCO) Annual Meeting. This will be
discussed during the company's joint Innovation Symposium with GE
Healthcare Monday, June
6th from 6:30 – 8:00 pm
CDT.
New agreement signed with GE Healthcare to
utilize Imaging Fabric to further accelerate radiomics analysis
workflows
Immunotherapy has revolutionized the management of metastatic
non-small cell lung cancer. Despite its promise, the majority of
patients fail to respond to the therapy while being exposed to
potentially severe side effects. Existing biomarkers are suboptimal
as they do not allow to predict which patients will benefit from
the therapy. There is an urgent need to identify biomarkers that
are predictive of response to immunotherapy at the individual
patient level.
SOPHiA GENETICS launched the DEEP-Lung-IV clinical study to
leverage its multimodal machine learning-powered analytics
capabilities to identify multimodal predictive signatures of
response to immunotherapy for patients with advanced lung cancer.
Through its global footprint, the study is intended to maximize
exposure of the machine learning algorithms to a wide range of
diverse, real-world data. Insights from the DEEP-Lung-IV study will
power one of the applications of the CarePath module of the SOPHiA
DDMTM platform, offering advanced data visualization,
cohorting, and predictive capabilities in a single solution.
To date, 19 sites across seven countries have signed up for
participation in the study, including Roswell Park Comprehensive
Cancer Center in New York. "I
am personally very excited to join the DEEP-Lung-IV study. I see
tremendous value in the multimodal machine learning-powered
approach to real-world data analytics and look forward to
potentially applying it to other clinical questions of high
relevance in lung cancer", said Dr. Prantesh Jain, Assistant
Professor of Oncology at Roswell Park Comprehensive Cancer Center.
Together, these sites have already recruited over 500 patients.
Early findings are promising and conceptually validate the
potential for multimodal signatures to predict response to
immuno-chemotherapy at the individual patient level. First results
will be discussed during SOPHiA GENETICS' joint Innovation
Symposium with GE Healthcare on Monday, June
6, at 6:30 pm CDT.
"We are very excited by the strong operational traction in
recruiting patients to the study, as well as the promising early
findings. With its unique machine learning-powered multimodal study
design and its focus on collecting very diverse real-world data
from lung cancer patients around the world, we feel that the
DEEP-Lung-IV study has the potential to usher a new era of
precision medicine that would enable predictions at the individual
patient level. We look forward to further validating our vision of
building a multimodal decentralized collective intelligence,
leveraging on real-world data to generate novel insights at the
individual patient level," said Dr. Philippe Menu, SVP &
Chief Medical Officer, SOPHiA
GENETICS.
SOPHiA GENETICS has also entered into an agreement with GE
Healthcare to utilize their Imaging Fabric Core and Imaging Fabric
Annotation Template, as part of the Edison Digital Health Platform.
In the context of the DEEP-Lung-IV clinical study, Imaging Fabric
services will be used to visualize, segment, and annotate lung
lesions for medical imaging visualization and annotation purposes.
This allows SOPHiA GENETICS to further accelerate proprietary
radiomics analytics workflows in the context of the study, in
particular to move towards automatic whole-body tumor
identification, segmentation, and quantification.
"We're eager to further strengthen our collaboration with
SOPHiA GENETICS. The use of Imaging Fabric and the SOPHiA
DDMTM Platform are key to create the world of tomorrow,
in which we aim to jointly break data silos across data modalities
to deliver insights to physicians to help them optimize patient
treatment workflows. We look forward to seeing how the
DEEP-Lung-IV study results can help improve outcomes for those
diagnosed with lung cancer," said Ben Newton, MD, General
Manager, GE Healthcare Oncology Solutions.
SOPHiA GENETICS' DEEP-Lung-IV clinical study aims to predict
immunotherapy treatment response upon first evaluation at the
individual patient level using data across multiple modalities
including genomics, radiomics, clinical, and biological data. The
study also aims to validate an algorithm that will allow the
prediction of outcomes of the individual patient such as
progression-free survival (PFS) and overall survival (OS). This
predictive model will help identify patients that are likely to
benefit from immunotherapy versus those that are not. It will
stratify patients according to risk, helping clinicians make more
informed therapeutic decisions for their patients, supporting
biopharma to ensure the right patients are selected for clinical
trials.
For more on the DEEP-Lung-IV clinical study, visit
https://clinicaltrials.gov/ct2/show/NCT04994795.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a health care technology
company dedicated to establishing the practice of data-driven
medicine as the standard of care and for life sciences research. It
is the creator of the SOPHiA DDM™ Platform, a cloud-native SaaS
platform capable of analyzing data and generating insights from
complex multimodal data sets and different diagnostic modalities.
The SOPHiA DDM™ Platform and related solutions, products and
services are currently used by more than 790 hospital, laboratory,
and biopharma institutions globally. For more information, visit
www.sophiagenetics.com, or connect on Twitter, LinkedIn and
Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-provides-an-update-on-its-deep-lung-iv-multimodal-clinical-study-at-asco-2022-301561906.html
SOURCE SOPHiA GENETICS